Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study.
about
Is metastatic pancreatic cancer an untargetable malignancy?Pancreatic cancerCXCR2: a target for pancreatic cancer treatment?Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II studySafety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patientsSequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.Evolution of systemic therapy for advanced pancreatic cancer.Current and emerging therapies for the treatment of pancreatic cancer.Pancreatic adenocarcinomaIntraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data.Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.Long-Term Relapse-Free Survival by Interdisciplinary Collaboration in a Patient with Metastatic Pancreatic Cancer (UICC IV).Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology).Nanovector-based therapies in advanced pancreatic cancer.The role of radiotherapy in management of pancreatic cancerA Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic CancerPrognostic factors in patients with pancreatic cancerPrognostic value of clinicopathological characteristics in patients with pancreatic cancerPancreatic Cancer: Progress in Systemic Therapy.Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.Metastatic pancreatic cancer: are we making progress in treatment?Meta-analyses of treatment standards for pancreatic cancer.Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.Pancreatic cancer--is the wall crumbling?Treatment of pancreatic cancer: what can we really predict today?Section III: Treatment of Advanced Gastrointestinal CancersFirst- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues.Accomplishments in 2007 in the management of localized pancreatic cancer.Pancreatic adenocarcinoma: new strategies for successErlotinib in the treatment of advanced pancreatic cancerCombined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings.Optimum chemotherapy in the management of metastatic pancreatic cancerResection of isolated local and metastatic recurrence in periampullary adenocarcinoma.Management of advanced pancreatic cancer.
P2860
Q26753849-258D7D0D-2807-4176-B9BC-EEA0B2FAD363Q27005724-38EC87AD-9D50-41D0-9CBF-88BBA3BA1942Q27021588-4E7EAF9C-5474-4579-89B2-B8AF3260993DQ33380084-4FF77E05-898E-457D-B9BD-5396E2DFAA2CQ33383758-E35B5C86-9752-4B35-B141-8AD11A1221DCQ33387945-846B681C-6C6A-4923-8A6C-27EA86BF83B9Q33396393-097582AF-CC08-4E31-9CC2-8AFCC67361B9Q33400095-E7E1A151-92F6-4188-A7CC-3BF1F7C3320DQ33557413-676EAFB5-9A6C-4B60-9877-934E17AA22C9Q34129346-BD4BC591-7B6A-415E-9670-29088CC60F91Q34140498-5B1CC0C4-6E25-4149-A066-00F1C1951BC8Q34152694-722871B1-2222-4AB6-992E-ADE6F485780EQ35048269-5398DA77-3537-4117-83C1-FF18760D9567Q35225658-66F6AE1C-411F-4E6B-B006-40C20674549FQ35648973-E3AC3E7B-8B9A-4AA7-A8B8-1E9957743A0DQ36097175-1E525332-2E93-475D-8D0D-34C2BF2E6EC2Q36097189-B72EB563-4F19-4D44-AAC3-4C85E1F5EAD1Q36153450-1D752DF9-4C78-4533-8058-B331FA046496Q36224397-E210EC17-56C3-4066-80B1-86B8B85AF88AQ36227127-DF05A800-888A-412E-A6C4-5111FB9231D2Q36344551-183E4BA7-85E6-480A-AC22-9898BFA0DE47Q36416279-F6F4DCB1-0D4A-4570-9387-92DF0E2AEDDEQ36469038-DC954EC4-C033-4CF4-9806-77DEA4A25A3AQ36640493-FF1AE4D1-8130-41D8-88CF-A748D33626F0Q37032865-3FF60B88-25AF-498C-99BF-AC10900BF7EFQ37074126-45B857BE-D4E3-47F5-AB71-9E8C97C1AEC3Q37125325-A868F9E9-AC2A-4340-8268-2B4A93D931F2Q37129815-23A41674-156C-4889-9294-1C71F69597CFQ37138161-1F2CFF09-4DA8-45BC-82FF-3B5D91BDD3EBQ37140954-82A28DB0-959F-4B52-83F1-3FDF392D822EQ37149172-22B3F393-90C5-4177-9E1C-E4EE4DB85339Q37198628-9B572E96-4DE9-4FAB-80A9-4EBE838DB63FQ37307567-D71A213E-C36B-491A-B457-510B66ECC8BFQ37346528-741CC3BC-3B96-491B-8A7C-D2CDE7251533Q37354443-4FD47C1F-5D25-4B10-912C-D49D087982D3Q37474061-3C6E6902-D08A-4EF4-B840-FC90A426BECBQ37584702-0AF8BFF0-2C19-44BD-8FD5-811B2977C258Q37617976-A584173A-C050-49CE-BBC6-9CC6691C3B1FQ37623488-9771D4B3-1820-421E-A28D-A0037EB516DEQ37960190-2BFFDAA0-3046-4914-9492-12F9A6473D85
P2860
Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Increased survival using plati ...... nd a German multicenter study.
@ast
Increased survival using plati ...... nd a German multicenter study.
@en
Increased survival using plati ...... nd a German multicenter study.
@nl
type
label
Increased survival using plati ...... nd a German multicenter study.
@ast
Increased survival using plati ...... nd a German multicenter study.
@en
Increased survival using plati ...... nd a German multicenter study.
@nl
prefLabel
Increased survival using plati ...... nd a German multicenter study.
@ast
Increased survival using plati ...... nd a German multicenter study.
@en
Increased survival using plati ...... nd a German multicenter study.
@nl
P2093
P356
P1433
P1476
Increased survival using plati ...... nd a German multicenter study.
@en
P2093
P304
P356
10.1093/ANNONC/MDM283
P577
2007-07-28T00:00:00Z